| Monograph Title
|
Monograph Section
|
Scientific Liaison
|
| DANTROLENE SODIUM CAPSULES PF 32(4) Pg. 1063
|
Title
|
|
| DANTROLENE SODIUM CAPSULES PF 32(4) Pg. 1063
|
Definition
|
|
| DANTROLENE SODIUM CAPSULES PF 32(4) Pg. 1063
|
Packaging and storage
|
|
| DANTROLENE SODIUM CAPSULES PF 32(4) Pg. 1063
|
USP Reference standards <11>
|
|
| DANTROLENE SODIUM CAPSULES PF 32(4) Pg. 1063
|
Identification
|
|
| DANTROLENE SODIUM CAPSULES PF 32(4) Pg. 1063
|
Dissolution <711>
|
|
| DANTROLENE SODIUM CAPSULES PF 32(4) Pg. 1063
|
Uniformity of dosage units <905>
|
|
| DANTROLENE SODIUM CAPSULES PF 32(4) Pg. 1063
|
Related compounds
|
|
| DANTROLENE SODIUM CAPSULES PF 32(4) Pg. 1063
|
Assay
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Title
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Pharmacopeial Discussion Group Sign-Off Document
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Chemical Info
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Chemical Info
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Definition
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Definition
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Packaging and storage
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Packaging and storage
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Labeling
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
USP Reference standards <11>
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Identification
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Identification
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Loss on ignition <733>
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Loss on ignition <733>
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Carbonate
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Carbonate
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Chloride <221>
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Chloride <221>
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Sulfate <221>
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Sulfate <221>
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Arsenic, Method I <211>
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Barium
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Barium
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Heavy metals, Method I <231>
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Limit of acid-insoluble substances
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Limit of acid-insoluble substances
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Limit of fluoride
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Organic volatile impurities, Method IV <467>
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Residual solvents <467>
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Assay
|
|
| DIBASIC CALCIUM PHOSPHATE PF 32(4) Pg. 1329
|
Assay
|
|
| DIDANOSINE PF 32(3) Pg. 781
|
Related compounds
|
|
| DOXAZOSIN TABLETS PF 29(1) Pg. 64
|
Dissolution
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Pharmacopeial Discussion Group Sign-Off Document
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Chemical Info
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Definition
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Definition
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Packaging and storage
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Packaging and storage
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
USP Reference standards <11>
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Identification
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Identification
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
pH <791>
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Chloride <221>
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Magnesium-chelating substances
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Disodium edetate
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Water, Method I <921>
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Water, Method I <921>
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Heavy metals, Method II <231>
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Limit of nitrilotriacetic acid
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Residual solvents <467>
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Assay
|
|
| EDETATE CALCIUM DISODIUM PF 32(4) Pg. 1335
|
Assay
|
|
| EDETATE DISODIUM INJECTION PF 32(4) Pg. 1071
|
Assay
|
|
| EDETATE DISODIUM PF 32(4) Pg. 1070
|
Assay
|
|
| ESTRADIOL AND NORETHINDRONE ACETATE TABLETS PF 31(5) Pg. 1364
|
Microbial limits
|
|
| FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(2) Pg. 403
|
Dissolution
|
|
| FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(2) Pg. 403
|
Title
|
|
| FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(2) Pg. 403
|
Definition
|
|
| FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(2) Pg. 403
|
Packaging and storage
|
|
| FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(2) Pg. 403
|
USP Reference standards
|
|
| FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(2) Pg. 403
|
Identification A, B
|
|
| FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(2) Pg. 403
|
Uniformity of dosage units
|
|
| FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(2) Pg. 403
|
Related compounds
|
|
| FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(2) Pg. 403
|
Assay
|
|
| FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(2) Pg. 403
|
Identification C
|
|
| FEXOFENADINE HYDROCHLORIDE CAPSULES PF 30(3) Pg. 845
|
Title
|
|
| FEXOFENADINE HYDROCHLORIDE CAPSULES PF 30(3) Pg. 845
|
Definition
|
|
| FEXOFENADINE HYDROCHLORIDE CAPSULES PF 30(3) Pg. 845
|
Packaging and storage
|
|
| FEXOFENADINE HYDROCHLORIDE CAPSULES PF 30(3) Pg. 845
|
USP Reference standards <11>
|
|
| FEXOFENADINE HYDROCHLORIDE CAPSULES PF 30(3) Pg. 845
|
Identification A, B
|
|
| FEXOFENADINE HYDROCHLORIDE CAPSULES PF 30(3) Pg. 845
|
Dissolution <711>
|
|
| FEXOFENADINE HYDROCHLORIDE CAPSULES PF 30(3) Pg. 845
|
Uniformity of dosage units <905>
|
|
| FEXOFENADINE HYDROCHLORIDE CAPSULES PF 30(3) Pg. 845
|
Related compounds
|
|
| FEXOFENADINE HYDROCHLORIDE CAPSULES PF 30(3) Pg. 845
|
Assay
|
|
| FEXOFENADINE HYDROCHLORIDE CAPSULES PF 32(5) Pg. 1449
|
Related compounds
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Title
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Title
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Chemical Info
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Chemical Info
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Definition
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Definition
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Packaging and storage
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Packaging and storage
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
USP Reference standards <11>
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Identification A, B, C
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Water, Method Ic <921>
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Residue on ignition <281>
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Heavy metals, Method II <231>
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Specific surface area, Method II <846>
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Limit of fexofenadine related compound B
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Related compounds
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Content of chloride
|
|
| FEXOFENADINE HYDROCHLORIDE PF 30(4) Pg. 1208
|
Assay
|
|
| FEXOFENADINE HYDROCHLORIDE PF 32(5) Pg. 1447
|
Labeling
|
|
| FEXOFENADINE HYDROCHLORIDE PF 32(5) Pg. 1447
|
Identification
|
|
| FEXOFENADINE HYDROCHLORIDE PF 32(5) Pg. 1447
|
Water, Method Ic <921>
|
|
| FEXOFENADINE HYDROCHLORIDE PF 32(5) Pg. 1447
|
Specific surface area, Method II <846>
|
|
| FEXOFENADINE HYDROCHLORIDE PF 32(5) Pg. 1447
|
Limit of fexofenadine related compound B
|
|
| FEXOFENADINE HYDROCHLORIDE PF 32(5) Pg. 1447
|
Related compounds
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Title
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Definition
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Packaging and storage
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
USP Reference standards
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Identification A, B
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
pH
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Particle size
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Foreign particulates
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Delivered dose uniformity (within container)
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Delivered dose uniformity (within batch)
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Related compounds
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Content of phenylethyl alcohol
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Content of benzalkonium chloride
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Assay
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Microbial limits
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Droplet size distribution
|
|
| FLUTICASONE PROPIONATE NASAL SPRAY PF 32(2) Pg. 339
|
Spray pattern
|
|
| FLUVOXAMINE MALEATE PF 32(5) Pg. 1449
|
Definition
|
|
| GLIPIZIDE AND METFORMIN HYDROCHLORIDE TABLETS PF 31(6) Pg. 1631
|
Title
|
|
| GLIPIZIDE AND METFORMIN HYDROCHLORIDE TABLETS PF 31(6) Pg. 1631
|
Definition
|
|
| GLIPIZIDE AND METFORMIN HYDROCHLORIDE TABLETS PF 31(6) Pg. 1631
|
Packaging and storage
|
|
| GLIPIZIDE AND METFORMIN HYDROCHLORIDE TABLETS PF 31(6) Pg. 1631
|
USP Reference standards
|
|
| GLIPIZIDE AND METFORMIN HYDROCHLORIDE TABLETS PF 31(6) Pg. 1631
|
Identification A, B, C
|
|
| GLIPIZIDE AND METFORMIN HYDROCHLORIDE TABLETS PF 31(6) Pg. 1631
|
Uniformity of dosage units
|
|
| GLIPIZIDE AND METFORMIN HYDROCHLORIDE TABLETS PF 31(6) Pg. 1631
|
Related compounds
|
|
| GLIPIZIDE AND METFORMIN HYDROCHLORIDE TABLETS PF 31(6) Pg. 1631
|
Chromatographic purity
|
|
| GLIPIZIDE AND METFORMIN HYDROCHLORIDE TABLETS PF 31(6) Pg. 1631
|
Assay for glipizide
|
|
| GLIPIZIDE AND METFORMIN HYDROCHLORIDE TABLETS PF 31(6) Pg. 1631
|
Assay for metformin hydrochloride
|
|
| GLIPIZIDE AND METFORMIN HYDROCHLORIDE TABLETS PF 32(4) Pg. 1076
|
Dissolution <711>
|
|
| GLIPIZIDE PF 32(5) Pg. 1453
|
USP Reference standards <11>
|
|
| GLIPIZIDE PF 32(5) Pg. 1453
|
Related compounds
|
|
| GLIPIZIDE PF 32(5) Pg. 1453
|
Assay
|
|
| GLUCOSAMINE AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1137
|
Title
|
|
| GLUCOSAMINE AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1137
|
Definition
|
|
| GLUCOSAMINE AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1137
|
Packaging and storage
|
|
| GLUCOSAMINE AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1137
|
Labeling
|
|
| GLUCOSAMINE AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1137
|
USP Reference standards <11>
|
|
| GLUCOSAMINE AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1137
|
Identification
|
|
| GLUCOSAMINE AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1137
|
Disintegration and dissolution <2040>
|
|
| GLUCOSAMINE AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1137
|
Weight variation <2091>
|
|
| GLUCOSAMINE AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1137
|
Content of glucosamine
|
|
| GLUCOSAMINE AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1137
|
Content of methylsulfonylmethane
|
|
| GLUCOSAMINE TABLETS PF 32(4) Pg. 1137
|
Disintegration and dissolution <2040>
|
|
| GLUCOSAMINE, CHONDROITIN SULFATE SODIUM, AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1138
|
Title
|
|
| GLUCOSAMINE, CHONDROITIN SULFATE SODIUM, AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1138
|
Definition
|
|
| GLUCOSAMINE, CHONDROITIN SULFATE SODIUM, AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1138
|
Packaging and storage
|
|
| GLUCOSAMINE, CHONDROITIN SULFATE SODIUM, AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1138
|
Labeling
|
|
| GLUCOSAMINE, CHONDROITIN SULFATE SODIUM, AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1138
|
USP Reference standards <11>
|
|
| GLUCOSAMINE, CHONDROITIN SULFATE SODIUM, AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1138
|
Identification
|
|
| GLUCOSAMINE, CHONDROITIN SULFATE SODIUM, AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1138
|
Disintegration and dissolution <2040>
|
|
| GLUCOSAMINE, CHONDROITIN SULFATE SODIUM, AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1138
|
Weight variation <2091>
|
|
| GLUCOSAMINE, CHONDROITIN SULFATE SODIUM, AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1138
|
Content of glucosamine
|
|
| GLUCOSAMINE, CHONDROITIN SULFATE SODIUM, AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1138
|
Content of chondroitin sulfate sodium
|
|
| GLUCOSAMINE, CHONDROITIN SULFATE SODIUM, AND METHYLSULFONYLMETHANE TABLETS PF 32(4) Pg. 1138
|
Content of methylsulfonylmethane
|
|
| GLYBURIDE TABLETS PF 32(4) Pg. 1080
|
Labeling
|
|
| GLYBURIDE TABLETS PF 32(4) Pg. 1080
|
Dissolution <711>
|
|
| GLYBURIDE TABLETS PF 32(4) Pg. 1080
|
Dissolution <711>
|
|
| GLYBURIDE TABLETS PF 32(4) Pg. 1080
|
Dissolution <711>
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
Title
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
Definition
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
Packaging and storage
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
Labeling
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
USP Reference standards <11>
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
Identification
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
Microbial limits <61>
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
Residue on ignition <281>
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
Heavy metals, Method II <231>
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
Total solids
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
Limit of sulfur dioxide
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
Limit of lead
|
|
| HIGH FRUCTOSE CORN SYRUP PF 32(4) Pg. 1151
|
Assay
|
|
| HYDROCORTISONE TABLETS PF 32(4) Pg. 1083
|
USP Reference standards <11>
|
|
| HYDROCORTISONE TABLETS PF 32(4) Pg. 1083
|
Uniformity of dosage units <905>
|
|
| HYDROCORTISONE TABLETS PF 32(4) Pg. 1083
|
Assay
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Title
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Clarity of solution
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Chemical Info
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Definition
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Packaging and storage
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Labeling
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
USP Reference standards <11>
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Identification
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Microbial limits <61>
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Heavy metals, Method I <231>
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Loss on drying <731>
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Conductivity
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Bacterial endotoxins <85>
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Sterility <71>
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Related compounds
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Molar substitution (see Nuclear Magnetic Resonance <761>)
|
|
| HYDROXYPROPYL BETADEX PF 32(5) Pg. 1481
|
Limit of propylene oxide
|
|
| HYDROXYZINE HYDROCHLORIDE PF 32(5) Pg. 1456
|
Definition
|
|
| HYDROXYZINE HYDROCHLORIDE PF 32(5) Pg. 1456
|
Chromatographic purity
|
|
| HYDROXYZINE HYDROCHLORIDE PF 32(5) Pg. 1456
|
Assay
|
|
| HYPROMELLOSE OPHTHALMIC SOLUTION PF 32(4) Pg. 1084
|
Assay
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
Title
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
Pharmacopeial Discussion Group Sign-Off Document
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
Definition
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
Packaging and storage
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
Labeling
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
Identification
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
Viscosity <911>
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
pH <791>
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
Heavy metals, Method III <231>
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
Loss on drying <731>
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
Residue on ignition <281>
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
Organic volatile impurities, Method IV <467>
|
|
| HYPROMELLOSE PF 32(5) Pg. 1573
|
Assay
|
|
| ISOMALT PF 32(4) Pg. 1154
|
Identification
|
|
| ISOMALT PF 32(4) Pg. 1154
|
Related compounds
|
|
| LEVODOPA PF 32(4) Pg. 1085
|
Related compounds
|
|
| LIDOCAINE AND PRILOCAINE CREAM PF 31(4) Pg. 1087
|
Related compounds
|
|
| LISINOPRIL TABLETS PF 32(4) Pg. 1086
|
Assay
|
|
| LOVASTATIN TABLETS PF 32(5) Pg. 1458
|
Dissolution
|
|
| LOVASTATIN TABLETS PF 32(5) Pg. 1458
|
Identification
|
|
| LOVASTATIN TABLETS PF 32(5) Pg. 1458
|
Assay
|
|
| MAGNESIUM HYDROXIDE PASTE PF 32(4) Pg. 1088
|
Definition
|
|
| MAGNESIUM HYDROXIDE PASTE PF 32(4) Pg. 1088
|
Soluble alkalies
|
|
| MAGNESIUM HYDROXIDE PASTE PF 32(4) Pg. 1088
|
Limit of lead
|
|
| MAGNESIUM HYDROXIDE PF 32(4) Pg. 1087
|
Lead <251>
|
|
| MAGNESIUM HYDROXIDE PF 32(4) Pg. 1087
|
Limit of lead
|
|
| MELOXICAM TABLETS PF 32(5) Pg. 1460
|
Title
|
|
| MELOXICAM TABLETS PF 32(5) Pg. 1460
|
Definition
|
|
| MELOXICAM TABLETS PF 32(5) Pg. 1460
|
Packaging and storage
|
|
| MELOXICAM TABLETS PF 32(5) Pg. 1460
|
USP Reference standards <11>
|
|
| MELOXICAM TABLETS PF 32(5) Pg. 1460
|
Identification
|
|
| MELOXICAM TABLETS PF 32(5) Pg. 1460
|
Uniformity of dosage units <905>
|
|
| MELOXICAM TABLETS PF 32(5) Pg. 1460
|
Related compounds
|
|
| MELOXICAM TABLETS PF 32(5) Pg. 1460
|
Assay
|
|
| METOPROLOL TARTRATE PF 32(4) Pg. 1089
|
Chromatographic purity
|
|
| MINERALS CAPSULES PF 32(5) Pg. 1474
|
Definition
|
|
| MINERALS TABLETS PF 32(5) Pg. 1474
|
Definition
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Title
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Chemical structure
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Chemical formula
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Molecular weight
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Chemical name
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
CAS number
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Definition
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Packaging and storage
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
USP Reference standards
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Identification
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Water
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Residue on ignition
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Heavy metals
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Related compounds
|
|
| MODAFINIL PF 30(5) Pg. 1634
|
Assay
|
|
| MODAFINIL TABLETS PF 30(5) Pg. 1636
|
Title
|
|
| MODAFINIL TABLETS PF 30(5) Pg. 1636
|
Definition
|
|
| MODAFINIL TABLETS PF 30(5) Pg. 1636
|
Packaging and storage
|
|
| MODAFINIL TABLETS PF 30(5) Pg. 1636
|
USP Reference standards
|
|
| MODAFINIL TABLETS PF 30(5) Pg. 1636
|
Identification A
|
|
| MODAFINIL TABLETS PF 30(5) Pg. 1636
|
Uniformity of dosage units
|
|
| MODAFINIL TABLETS PF 30(5) Pg. 1636
|
Related compounds
|
|
| MODAFINIL TABLETS PF 30(5) Pg. 1636
|
Assay
|
|
| MODAFINIL TABLETS PF 30(5) Pg. 1636
|
Dissolution
|
|
| MUPIROCIN CREAM PF 31(2) Pg. 432
|
Microbial limits
|
|
| NARATRIPTAN HYDROCHLORIDE PF 32(5) Pg. 1462
|
Assay
|
|
| NEFAZODONE HYDROCHLORIDE PF 32(5) Pg. 1462
|
Related compounds
|
|
| NETILMICIN SULFATE PF 32(4) Pg. 1089
|
Definition
|
|
| NETILMICIN SULFATE PF 32(4) Pg. 1089
|
Assay
|
|
| NEVIRAPINE ORAL SUSPENSION PF 32(4) Pg. 1090
|
Title
|
|
| NEVIRAPINE ORAL SUSPENSION PF 32(4) Pg. 1090
|
Definition
|
|
| NEVIRAPINE ORAL SUSPENSION PF 32(4) Pg. 1090
|
Packaging and storage
|
|
| NEVIRAPINE ORAL SUSPENSION PF 32(4) Pg. 1090
|
USP Reference standards <11>
|
|
| NEVIRAPINE ORAL SUSPENSION PF 32(4) Pg. 1090
|
Identification
|
|
| NEVIRAPINE ORAL SUSPENSION PF 32(4) Pg. 1090
|
Microbial limits <61>
|
|
| NEVIRAPINE ORAL SUSPENSION PF 32(4) Pg. 1090
|
Dissolution <711>
|
|
| NEVIRAPINE ORAL SUSPENSION PF 32(4) Pg. 1090
|
Related compounds
|
|
| NEVIRAPINE ORAL SUSPENSION PF 32(4) Pg. 1090
|
Assay
|
|
| NORGESTIMATE PF 32(4) Pg. 1094
|
USP Reference standards <11>
|
|
| NORGESTIMATE PF 32(4) Pg. 1094
|
Chromatographic purity
|
|
